Dr Kumar Prabhash's commentary: Gefitinib vs. Gefitinib plus Pemetrexed and Carboplatin chemotherapy in EGFR-Mutated lung cancer

M3 India Newsdesk Aug 20, 2019

A clinical study by Dr. Kumar Prabhash and his team was published in JCO in the month of August 2019 which concluded that adding pemetrexed and carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but increased toxicity in patients with NSCLC.

 

 

 

 

This was a phase III randomised trial in patients with advanced NSCLC harboring an EGFR-sensitising mutation and a performance status of 0 to 2.

Key Takeaways

1. TKI with chemotherapy improves outcome in EGFR Mutation lung cancer patients

2. This combination doubles the disease control

3. This is a new standard treatment option for these patients

4. We have potential to develop effective treatment for patients in our country


Dr Kumar Prabhash's commentry

In EGFR mutation positive lung cancer TKI is better than chemotherapy. This study shows that the disease can be controlled better with TKI and chemotherapy as compared with TKI alone. At present other options which control the disease with similar effect is TKI (osimertinib).

We know that osimertinib works in second line setting also.This brings the discussion of appropriate sequencing of treatment in clinic.Due to cost implication only less than 5% patients can take this drug (osimertinib).

As compared this combination used in this study can be used by almost any patient in our country. This highlights the development of treatment in the country which is as effective as the treatment which is very costly and only 5% of patients can take it.


To access the original article abstract click this link: https://ascopubs.org/doi/full/10.1200/JCO.19.01154

 

M3 India is hosting a Live Webinar with Dr Kumar Prabhash on 31st August 2019.

Click here to register and get a chance to have your questions answered by the expert himself.
 

 

Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay